

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/618,531
Filing Date	July 11, 2003
First Named Inventor	Philip A. Furman
Art Unit	1614
Examiner Name	Donna Jagoe
Attorney Docket Number	04674.105074 (TRI 1016)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Alexander, "Treatment of Acute and Chronic Viral Hepatitis," Therapy of Liver Disease. Bailliere's Clinical Gastroenterology series, London, Bailliere Tindall, January 1989, 3:1-20	
		Alexander et al., "Loss of HBsAg with Interferon Therapy in Chronic Hepatitis B Virus Infection," Lancet, July 11, 1987, 2(8550):66-69	
		Lau et al., "Viral Hepatitis," Gut Supplement, 1991, S47-S62	
		Sheron et al., "Tumour Necrosis Factor to Treat Chronic Hepatitis B Virus Infection," Lancet, August 4, 1990, 336:321-322	

Examiner  
Signature

/Donna Jagoe/ (09/23/2008)

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.J./